Related Experiment Video
Updated: May 28, 2026

Producing Gene Deletions in Escherichia coli by P1 Transduction with Excisable Antibiotic Resistance Cassettes
Published on: September 1, 2018
A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent
Vivek Daniel Paul1, Sanjeev Saravanan Rajagopalan, Sudarson Sundarrajan
1Gangagen Biotechnologies Pvt Ltd, Raghavendra Layout, Tumkur Road, Yeshwantpur, Bangalore 560022, India.
Background:
Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. However, the rapid emergence of antibiotic resistance limits the choice of therapeutic options for treating infections caused by this organism. Muralytic enzymes from bacteriophages have recently gained attention for their potential as antibacterial agents against antibiotic-resistant gram-positive organisms. Phage K is a polyvalent virulent phage of the Myoviridae family that is active against many Staphylococcus species.
Results:
We identified a phage K gene, designated orf56, as encoding the phage tail-associated muralytic enzyme (TAME). The gene product (ORF56) contains a C-terminal domain corresponding to cysteine, histidine-dependent amidohydrolase/peptidase (CHAP), which demonstrated muralytic activity on a staphylococcal cell wall substrate and was lethal to S. aureus cells. We constructed N-terminal truncated forms of ORF56 and arrived at a 16-kDa protein (Lys16) that retained antistaphylococcal activity. We then generated a chimeric gene construct encoding Lys16 and a staphylococcal cell wall-binding SH3b domain. This chimeric protein (P128) showed potent antistaphylococcal activity on global clinical isolates of S. aureus including methicillin-resistant strains. In addition, P128 was effective in decolonizing rat nares of S. aureus USA300 in an experimental model.
Conclusions:
We identified a phage K gene that encodes a protein associated with the phage tail structure. The muralytic activity of the phage K TAME was localized to the C-terminal CHAP domain. This potent antistaphylococcal TAME was combined with an efficient Staphylococcus-specific cell-wall targeting domain SH3b, resulting in the chimeric protein P128. This protein shows bactericidal activity against globally prevalent antibiotic resistant clinical isolates of S. aureus and against the genus Staphylococcus in general. In vivo, P128 was efficacious against methicillin-resistant S. aureus in a rat nasal colonization model.
Insights
Researchers identified a phage K gene encoding a muralytic enzyme (TAME) with potent antibacterial activity against Staphylococcus aureus. A modified enzyme, P128, effectively targets and kills antibiotic-resistant strains, including in vivo models.
Area of Science:
- Microbiology
- Biochemistry
- Molecular Biology
Background:
- Staphylococcus aureus is a significant cause of hospital and community infections.
- Antibiotic resistance in S. aureus limits treatment options.
- Bacteriophage-derived muralytic enzymes show promise against resistant gram-positive bacteria.
Purpose of the Study:
- Identify and characterize novel antibacterial agents from bacteriophages.
- Develop a potent therapeutic agent against antibiotic-resistant S. aureus.
- Evaluate the efficacy of a novel chimeric protein in vitro and in vivo.
Main Methods:
- Identified a gene (orf56) encoding a phage tail-associated muralytic enzyme (TAME) from bacteriophage K.
- Characterized the muralytic activity of the TAME's CHAP domain.
- Constructed a chimeric protein (P128) by combining a truncated TAME (Lys16) with an SH3b cell-wall binding domain.
Main Results:
- The TAME's C-terminal CHAP domain exhibited muralytic activity and was lethal to S. aureus.
- The chimeric protein P128 demonstrated potent antistaphylococcal activity against diverse clinical isolates, including MRSA.
- P128 effectively reduced S. aureus USA300 nasal colonization in a rat model.
Conclusions:
- A novel phage K-derived muralytic enzyme (TAME) with bactericidal activity against S. aureus was identified.
- The chimeric protein P128, combining TAME with a cell-wall binding domain, shows broad-spectrum efficacy against S. aureus.
- P128 is a promising candidate for treating infections caused by antibiotic-resistant S. aureus, demonstrating in vivo efficacy.
Related Concept Videos
DNA Bacteriophages
Viral Replication: Lytic Cycle
Bacterial Protein Maturation

